title: [A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy].
abstract: A 59-year-old man was admitted to our hospital for abdominal mass and found to have a gastric cancer with peritoneal dissemination. Three courses of neoadjuvant chemotherapy combined with S-1 and CDDP were performed. This chemotherapy showed a substantial reduction of the size of primary tumor and peritoneal dissemination by CT examination. Surgical resection consisted of distal gasterectomy and D2 lymph node dissection was performed, and an ip catheter was placed through the douglas pouch, and the catheter was attached to the subcutaneous portal delivery system for ip chemotherapy. Operative cytology of ascites proved positive and remnant neoplasm cells were identified in the peritoneum. The pathological stage was determined as T3 N2 H0 P1 CY1 M0, pStage IV. Following surgery, we selected the ip administration of paclitaxel at a dose of 100 mg per body. Finally, the peritoneal dissemination was re-grown. However, we continued the ip chemotherapy for twenty-five times on ambulant basis. Most gastric cancer patients with peritoneal dissemination die within a few months, and there is no standard treatment for peritoneal dissemination from gastric cancer. In conclusion, a condition of no progression has been achieved and maintained for more than three years by intraperitoneal administration of paclitaxel for patient with peritoneal dissemination due to advanced gastric cancer.
authors.affiliation: Department of Surgery, Fukuyama City Hospital.
authors.forename: Shinya
authors.initials: S
authors.lastname: Asami
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Idani
authors.forename: Shinichirou
authors.initials: S
authors.lastname: Kubo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sasaki
authors.forename: Youhei
authors.initials: Y
authors.lastname: Kurose
authors.forename: Hiroki
authors.initials: H
authors.lastname: Nojima
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshioka
authors.forename: Masahiko
authors.initials: M
authors.lastname: Muro
authors.forename: Kenjirou
authors.initials: K
authors.lastname: Kumano
authors.forename: Masataka
authors.initials: M
authors.lastname: Hirata
authors.forename: Tetsumasa
authors.initials: T
authors.lastname: Yamashita
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kin
authors.forename: Norihisa
authors.initials: N
authors.lastname: Takakura
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005743:Gastrectomy; D006801:Humans; D007263:Infusions, Parenteral; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000556:secondary* / Q000601:surgery; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel; D002945:Cisplatin